ReviewTherapeutic advances in gastroenterology2020
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review.
Review in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07522255 (The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Bidirectional Communication of the Gut-Brain Axis in Pain Regulation: From Microbial Metabolites to Neuroinflammation.Journal of inflammation research · 2026Review
- Rifaximin as a Therapeutic Ally in the Modulation of Dysbiosis: A Narrative Review of Its Applicability in Gastrointestinal Disorders.GE Portuguese journal of gastroenterology · 2025Review
- Advancing Gastrointestinal Microbiota Research in Systemic Sclerosis: Lessons Learned from Prior Research and Opportunities to Accelerate Discovery.Rheumatic diseases clinics of North America · 2025Review
- [Treatment of Irritable Bowel Syndrome with Predominant Diarrhea].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
- Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation onFrontiers in medicine · 2025Article
- A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.Journal of clinical medicine · 2024Review
- Functional Abdominal Bloating and Gut Microbiota: An Update.Microorganisms · 2024Review
- Survey-Based Analysis of the Clinical Treatment Status of Irritable Bowel Syndrome in Korea.Journal of Korean medical science · 2023Article
- Rifaximin Protects against Malathion-Induced Rat Testicular Toxicity: A Possible Clue on Modulating Gut Microbiome and Inhibition of Oxidative Stress by Mitophagy.Molecules (Basel, Switzerland) · 2022Article
- Polyphenols from Olive-Mill Wastewater and Biological Activity: Focus on Irritable Bowel Syndrome.Nutrients · 2022Article
- Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats.BMC neuroscience · 2022Article
- Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray.Frontiers in physiology · 2022Article
- Article
- Article
- The Effect of Bacterial Infections, Probiotics and Zonulin on Intestinal Barrier Integrity.International journal of molecular sciences · 2021Review
- Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.Frontiers in chemistry · 2021Review
- Microbiotal characteristics colonized in intestinal mucosa of mice with diarrhoea and repeated stress.3 Biotech · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy individuals. After a bout of acute gastroenteritis, postinfection IBS may result in up to approximately 10% of those affected. Small intestinal bacterial overgrowth (SIBO) is more common in patients with IBS than in healthy individuals, and eradication of SIBO with systemic antibiotics has decreased symptoms of IBS in some patients with IBS and SIBO. The nonsystemic (i.e. low oral bioavailability) antibiotic rifaximin is indicated in the United States and Canada for the treatment of adults with IBS with diarrhea (IBS-D). The efficacy and safety of 2-week single and repeat courses of rifaximin have been demonstrated in randomized, placebo-controlled studies of adults with IBS. Rifaximin is widely thought to exert its beneficial clinical effects in IBS-D through manipulation of the gut microbiota. However, current studies indicate that rifaximin induces only modest effects on the gut microbiota of patients with IBS-D, suggesting that the efficacy of rifaximin may involve other mechanisms. Indeed, preclinical data reveal a potential role for rifaximin in the modulation of inflammatory cytokines and intestinal permeability, but these two findings have not yet been examined in the context of clinical studies. The mechanism of action of rifaximin in IBS is likely multifactorial, and further study is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.